DNLI Latest Press Releases

-- July 9, 2026 --

Denali Therapeutics to Give Opening Plenary Address at Alzheimer's Association International Conference (AAIC) 2026 and Highlight Breakthroughs in Delivering Biologic Therapies Across Blood-Brain Barrier Globe Newswire 4:01 PM

-- June 18, 2026 --

Denali Therapeutics Enters Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $195 Million Globe Newswire 8:00 AM

-- May 21, 2026 --

Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson's Disease Globe Newswire 6:00 PM

-- May 7, 2026 --

Denali Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights Globe Newswire 4:01 PM

-- April 20, 2026 --

When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech Globe Newswire 8:30 AM

-- April 3, 2026 --

Denali Therapeutics Regains Full Rights to Investigational Therapy DNL593 (PTV:PGRN) for GRN-related Frontotemporal Dementia (FTD-GRN) Globe Newswire 1:30 PM

-- March 25, 2026 --

Denali Therapeutics Announces U.S. FDA Approval of AVLAYAH (tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II) Globe Newswire 11:50 AM

-- February 26, 2026 --

Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights Globe Newswire 4:01 PM

-- February 19, 2026 --

Drug-Delivery Breakthroughs, Cross-Indication Research Accelerate New Momentum in CNS and Oncology Development Globe Newswire 8:30 AM

Market Data Delayed 15 Minutes

Questions? Feedback?Olark live chat software